BioMérieux: Invest Securities raises TP

(CercleFinance.com) - Invest Securities reiterates its 'buy' rating on bioMérieux shares, raising its target price for them from E120 to E123, following a CMD that validates its preference for the group in the in vitro diagnostics market.


Alongside the quarterly publication marked by a further outperformance in molecular diagnostics, the group presented attractive but unsurprising medium-term targets, the analyst says.

While the CMD offers appreciable visibility on post-Covid prospects, Invest Securities corrects the margin dynamic by including a strong acceleration from 2026 onwards, marginally impacting its 2024-25 EPS estimates.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.